BI Asset Management Fondsmaeglerselskab A S Increases Position in DexCom, Inc. (NASDAQ:DXCM)

BI Asset Management Fondsmaeglerselskab A S raised its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 55.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,594 shares of the medical device company's stock after acquiring an additional 13,782 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in DexCom were worth $3,001,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of DXCM. Geode Capital Management LLC boosted its position in shares of DexCom by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after purchasing an additional 56,094 shares during the period. Jennison Associates LLC grew its position in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after acquiring an additional 710,858 shares during the last quarter. Norges Bank acquired a new position in DexCom in the fourth quarter valued at $385,367,000. Charles Schwab Investment Management Inc. grew its holdings in shares of DexCom by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock worth $219,716,000 after buying an additional 91,051 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its position in DexCom by 12.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company's stock valued at $144,152,000 after acquiring an additional 201,181 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company's stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock worth $8,044,178 in the last three months. 0.32% of the stock is currently owned by company insiders.

DexCom Trading Up 1.2 %

Shares of NASDAQ DXCM traded up $0.88 on Friday, reaching $71.66. 2,857,741 shares of the company traded hands, compared to its average volume of 4,236,941. The stock has a market capitalization of $28.10 billion, a PE ratio of 50.11, a P/E/G ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $139.24. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average of $73.46 and a 200 day moving average of $76.61.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on DXCM shares. Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and raised their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Citigroup boosted their target price on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Canaccord Genuity Group upped their price objective on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $99.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.